Salil Sharma of Kapoor Sharma and Company feels that one should hold Cadila Healthcare .
Sharma told CNBC-Awaaz, "Investors should hold Cadila Healthcare with a stoploss of Rs 815. The stock is going down since 1-1.5 months. If the stock breaks this support level then exit it and invest in Wockhardt and Ranbaxy."
The company's trailing 12-month (TTM) EPS was at Rs 26.59 per share. (Jun, 2011). The stock's price-to-earnings (P/E) ratio was 31.37. The latest book value of the company is Rs 102.07 per share. At current value, the price-to-book value of the company was 8.17. The dividend yield of the company was 0.75%.
